Purchase this article with an account.
Geoffrey P. Lewis, Ethan A. Chapin, Jiyun Byun, Gabriel Luna, David Sherris, Steven K. Fisher; Müller Cell Reactivity and Photoreceptor Cell Death Are Reduced after Experimental Retinal Detachment Using an Inhibitor of the Akt/mTOR Pathway. Invest. Ophthalmol. Vis. Sci. 2009;50(9):4429-4435. doi: 10.1167/iovs.09-3445.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To test the effect of Palomid 529, an inhibitor of the Akt/mTOR pathway, on Müller cell proliferation, subretinal glial scar formation, and photoreceptor survival after experimental retinal detachment (RD).
methods. Palomid 529 (600 μg) in balanced salt solution or balanced salt solution alone was injected intravitreally immediately after RD into the right eyes of 12 rabbits. Ten micrograms of BrdU was injected intravitreally on day 3. Animals were killed on day 3 or 7, at which time retinal sections were labeled with anti-BrdU to detect dividing cells, with anti-vimentin to identify Müller cells, and with the isolectin B4 to identify microglia and macrophages. Outer nuclear layer (ONL) thickness was measured from fluorescence-labeled nuclear-stained sections. Labeling was imaged using confocal microscopy. Six additional animals received either drug or balanced salt solution injections into normal eyes, and paraffin sections were stained with hematoxylin and eosin.
results. In the drug-treated eyes there was a significant decrease in the number of anti-BrdU–labeled Müller cells, the number and size of subretinal scars, and the number of isolectin B4-labeled cells. The ONL was also significantly thicker, and there was no evidence of toxic effects.
conclusions. Palomid 529 is an effective suppressor of Müller cell proliferation, glial scar formation, and photoreceptor cell death in a rabbit model of RD. This suggests that inhibiting the Akt/mTOR signal transduction pathway may be an effective strategy to decrease proliferation and photoreceptor cell death induced by detachment and perhaps represents a novel therapy for related human diseases such as proliferative vitreoretinopathy.
This PDF is available to Subscribers Only